Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Rising High: CannTrust obtains order under CCAA as firms report earnings » 11:11
04/02/20
04/02
11:11
04/02/20
11:11
CTST

CannTrust

$0.64 /

+ (+0.00%)

, CRON

Cronos Group

$5.46 /

+0.21 (+4.00%)

, GNLN

Greenlane

$1.69 /

+0.15 (+9.74%)

, HEXO

Hexo

$0.74 /

+0.0619 (+9.07%)

, MEDIF

Medipharm Labs

$0.00 /

+ (+0.00%)

, APHA

Aphria

$2.97 /

+0.13 (+4.58%)

, OGI

Organigram

$1.85 /

+0.055 (+3.06%)

, MJARF

MJardin Group

$0.00 /

+ (+0.00%)

, ACB

Aurora Cannabis

$0.88 /

+0.0746 (+9.29%)

, CVSI

CV Sciences

$0.00 /

+ (+0.00%)

, CGC

Canopy Growth

$14.24 /

+0.68 (+5.01%)

, CANN

General Cannabis

$0.00 /

+ (+0.00%)

, IGC

India Globalization Capital

$0.46 /

+0.015 (+3.41%)

, TLRY

Tilray

$6.40 /

+0.55 (+9.40%)

, TCNNF

Trulieve Cannabis

$0.00 /

+ (+0.00%)

, ZYNE

Zynerba

$3.43 /

+0.01 (+0.29%)

In this week's "Rising…

Open Full Text

ShowHide Related Items >><<
CTST CannTrust
$0.64 /

+ (+0.00%)

07/12/19
CannTrust downgraded to Sell from Neutral at Eight Capital
07/09/19 Roth Capital
CannTrust downgraded to Neutral from Buy at Roth Capital
07/08/19
CannTrust downgraded to Neutral from Buy at Eight Capital
07/08/19 BofA
BofA double downgrades CannTrust to Underperform after Health Canada probe
CRON Cronos Group
$5.46 /

+0.21 (+4.00%)

04/02/20 BofA
Cronos Group downgraded to Neutral from Buy at BofA
04/02/20 BofA
Cronos Group downgraded to Neutral from Buy at BofA
03/31/20
Fly Intel: Top five analyst downgrades
03/31/20 Canaccord
Cronos Group downgraded to Sell at Canaccord
GNLN Greenlane
$1.69 /

+0.15 (+9.74%)

03/31/20 Roth Capital
Greenlane price target lowered to $4 from $9 at Roth Capital
10/07/19 Roth Capital
Greenlane price target lowered to $10 from $18.50 at Roth Capital
06/21/19
Former FDA head sees difficulty in JUUL getting PMTA approval, says Cowen
06/20/19 Cowen
Greenlane fundamentals remain intact, selloff 'overdone,' says Cowen
HEXO Hexo
$0.74 /

+0.0619 (+9.07%)

03/31/20 BofA
Hexo resumed with an Underperform at BofA
03/31/20 Desjardins
Hexo downgraded to Hold from Buy at Desjardins
03/18/20 BMO Capital
Hexo downgraded to Underperform from Market Perform at BMO Capital
MEDIF Medipharm Labs
$0.00 /

+ (+0.00%)

08/07/19 Roth Capital
Medipharm Labs initiated with a Buy at Roth Capital
APHA Aphria
$2.97 /

+0.13 (+4.58%)

04/01/20 Cantor Fitzgerald
Aphria price target lowered to C$9.30 from C$11.50 at Cantor Fitzgerald
03/19/20 BofA
Organigram upgraded to Neutral from Underperform at BofA
03/19/20 BofA
Aphria upgraded to Buy from Neutral at BofA, price target lowered to C$5
03/19/20 BofA
Aphria upgraded to Buy from Neutral at BofA
OGI Organigram
$1.85 /

+0.055 (+3.06%)

04/01/20 Cantor Fitzgerald
Organigram price target lowered to C$5.80 from C$9.00 at Cantor Fitzgerald
01/15/20
Fly Intel: Top five analyst upgrades
01/15/20 Raymond James
Organigram upgraded to Outperform from Market Perform at Raymond James
MJARF MJardin Group
$0.00 /

+ (+0.00%)

05/08/19 Canaccord
MJardin Group downgraded to Hold from Speculative Buy at Canaccord
ACB Aurora Cannabis
$0.88 /

+0.0746 (+9.29%)

02/27/20 Bryan Garnier
Aurora Cannabis downgraded to Sell from Neutral at Bryan Garnier
02/25/20 Needham
Aurora Cannabis initiated with a Hold at Needham
02/24/20 Cowen
Cowen cautious on Canada cannabis, downgrades Aurora, Sundial, Tilray
02/24/20 Cantor Fitzgerald
Cantor still 'comfortable' recommending shares of Aurora Cannabis
CVSI CV Sciences
$0.00 /

+ (+0.00%)

03/17/20 Roth Capital
CV Sciences downgraded to Neutral from Buy at Roth Capital
03/09/20 Cantor Fitzgerald
CV Sciences price target lowered to $1.60 from $4.20 at Cantor Fitzgerald
11/07/19 Cantor Fitzgerald
Cantor Fitzgerald expects industry consolidation in consumer CBD wellness trend
11/07/19 Cantor Fitzgerald
CV Sciences initiated with an Overweight at Cantor Fitzgerald
CGC Canopy Growth
$14.24 /

+0.68 (+5.01%)

03/27/20 SunTrust
Constellation Brands upgraded to Buy from Hold at SunTrust
03/23/20 BofA
Most Canadian cannabis stores remain open amidst demand surge, says BofA
03/05/20 BofA
Canopy Growth's 'bold' capacity cut a 'clear positive,' says BofA
CANN General Cannabis
$0.00 /

+ (+0.00%)

11/05/19 BofA
BofA says Mexico cannabis legalization 'still in play' in 2020 after extension
10/10/19 Stifel
Hexo miss further damages cannabis industry credibility, says Stifel
09/26/19 Compass Point
Cannabis banking bill should find path to passage in Senate, says Compass Point
06/10/19 Piper Sandler
Cannabis regulation could become top 2020 election issue, says Piper Jaffray
IGC India Globalization Capital
$0.46 /

+0.015 (+3.41%)

TLRY Tilray
$6.40 /

+0.55 (+9.40%)

03/23/20 Roth Capital
Tilray price target lowered to $4 from $15 at Roth Capital
03/19/20 BofA
Tilray downgraded to Underperform from Neutral at BofA
03/16/20 Cantor Fitzgerald
Tilray price target lowered to $4.90 from $17.50 at Cantor Fitzgerald
03/04/20 GLJ Research
Tilray price target lowered to $0 from $5 at GLJ Research
TCNNF Trulieve Cannabis
$0.00 /

+ (+0.00%)

02/14/20 Cantor Fitzgerald
Cantor initiates 10 cannabis names, sees opportunity after sellofff
02/13/20 Cantor Fitzgerald
Trulieve Cannabis initiated with an Overweight at Cantor Fitzgerald
12/16/19 Craig-Hallum
Trulieve Cannabis initiated with a Buy at Craig-Hallum
12/03/19 Needham
Trulieve Cannabis initiated with a Buy at Needham
ZYNE Zynerba
$3.43 /

+0.01 (+0.29%)

03/11/20 Canaccord
Zynerba risk/reward remains favorable at current levels, says Canaccord
12/31/19
Fly Intel: Top five analyst actions
12/31/19 Roth Capital
Zynerba assumed with a Buy at Roth Capital
12/16/19 Canaccord
Zynerba's Zygel may have 'clear place' as DEE treatment, says Canaccord
Recommendations
Greenlane price target lowered to $4 from $9 at Roth Capital » 09:03
03/31/20
03/31
09:03
03/31/20
09:03
GNLN

Greenlane

$1.87 /

-0.26 (-12.21%)

Roth Capital analyst…

Roth Capital analyst Scott Fortune lowered the firm's price target on Greenlane to $4 from $9 and keeps a Buy rating on the shares. The analyst notes that the company reported Q4 revenues of $37.2M, off 28%, due to less emphasis on JUUL, a weak rebound in national vape demand, and a 2.0 roll-out delay in Canada, ahead of COVID-19 disruption to its distribution nationally.

ShowHide Related Items >><<
GNLN Greenlane
$1.87 /

-0.26 (-12.21%)

10/07/19 Roth Capital
Greenlane price target lowered to $10 from $18.50 at Roth Capital
06/21/19
Former FDA head sees difficulty in JUUL getting PMTA approval, says Cowen
06/20/19 Cowen
Greenlane fundamentals remain intact, selloff 'overdone,' says Cowen
05/14/19 Roth Capital
Greenlane initiated with a Buy at Roth Capital
Earnings
Greenlane reports Q4 EPS (27c), consensus (7c) » 07:16
03/30/20
03/30
07:16
03/30/20
07:16
GNLN

Greenlane

$2.13 /

-0.37 (-14.80%)

Reports Q4 revenue…

Reports Q4 revenue $37.24M, consensus $38.36M. Aaron LoCascio, Greenlane's Chairman and Chief Executive Officer, said, "2019 was a historic year for us. We are proud of the progress we made in our first year as a public company - in particular, our ability to advance our business goals while navigating turbulent industry headwinds throughout the year. Over the second half of the year, we undertook a large-scale shift in our business model by beginning to successfully move away from high-volume, low-margin products and sales, in favor of high-margin sales and the promotion of our house brands and products. We've concentrated on identifying cost-cutting opportunities and putting in place a thoughtful plan to leverage our scale to drive sustained, long-term growth and profitability. We believe the sequential increase of our fourth quarter margins by 396 basis points demonstrates the strength of our business and our ability to adapt to changing market conditions, while continuing to deliver on our targets. We are confident these steps best position us to become cash-flow positive in the near future, as we move forward."

ShowHide Related Items >><<
GNLN Greenlane
$2.13 /

-0.37 (-14.80%)

10/07/19 Roth Capital
Greenlane price target lowered to $10 from $18.50 at Roth Capital
06/21/19
Former FDA head sees difficulty in JUUL getting PMTA approval, says Cowen
06/20/19 Cowen
Greenlane fundamentals remain intact, selloff 'overdone,' says Cowen
05/14/19 Roth Capital
Greenlane initiated with a Buy at Roth Capital
Over a quarter ago
Hot Stocks
Fly Intel: After Hours Movers » 18:25
01/07/20
01/07
18:25
01/07/20
18:25
PIXY

ShiftPixy

$7.75 /

-0.26 (-3.25%)

, GRTX

Galera Therapeutics

$15.79 /

+1.23 (+8.45%)

, GNLN

Greenlane

$3.03 /

-0.06 (-1.94%)

, CPIX

Cumberland

$5.29 /

+0.16 (+3.12%)

, EXFO

EXFO Inc.

$4.89 /

+0.055 (+1.14%)

, LTHM

Livent

$8.67 /

+0.25 (+2.97%)

, RADA

RADA Electronic

$6.30 /

-0.17 (-2.63%)

, SPNE

SeaSpine

$13.04 /

+0.49 (+3.90%)

, PNM

PNM Resources

$49.15 /

-0.64 (-1.29%)

HIGHER: ShiftPixy (PIXY),…

HIGHER: ShiftPixy (PIXY), up 200.7% after completing its recapitalization... Galera (GRTX), up 12.8% after announcing initial dosing in its Phase 2a clinical trial of GC4419... Greenlane (GNLN), up 12.6% after announcing a distribution agreement with AVD... Cumberland (CPIX), up 1.9% after announcing the national launch of a new Caldolor ready-to-use product. DOWN AFTER EARNINGS: EXFO (EXFO), down 16.1%. ALSO LOWER: Livent (LTHM), down 13.3% after providing guidance for Q4, fiscal 2019, and fiscal 2020... RADA Electronic (RADA), down 8.4% after it filed to sell common stock... SeaSpine (SPNE), down 4.3% after providing Q4 and FY20 revenue guidance... PNM Resources (PNM), down 3.2% after it filed to sell 4.9M shares of common stock.

ShowHide Related Items >><<
PIXY ShiftPixy
$7.75 /

-0.26 (-3.25%)

GRTX Galera Therapeutics
$15.79 /

+1.23 (+8.45%)

12/02/19 BTIG
Galera Therapeutics initiated with a Buy at BTIG
12/02/19 Credit Suisse
Galera Therapeutics initiated with a Neutral at Credit Suisse
12/02/19 Citi
Galera Therapeutics initiated with a Buy at Citi
12/02/19 BofA
Galera Therapeutics initiated with a Buy at BofA/Merrill
GNLN Greenlane
$3.03 /

-0.06 (-1.94%)

10/07/19 Roth Capital
Greenlane price target lowered to $10 from $18.50 at Roth Capital
06/21/19
Former FDA head sees difficulty in JUUL getting PMTA approval, says Cowen
06/20/19 Cowen
Greenlane fundamentals remain intact, selloff 'overdone,' says Cowen
05/14/19 Roth Capital
Greenlane initiated with a Buy at Roth Capital
CPIX Cumberland
$5.29 /

+0.16 (+3.12%)

EXFO EXFO Inc.
$4.89 /

+0.055 (+1.14%)

LTHM Livent
$8.67 /

+0.25 (+2.97%)

10/23/19 Goldman Sachs
Buy Albemarle and Livent on 'compelling' contrarian call, says Goldman Sachs
08/12/19 BofA
Livent downgraded to Underperform from Neutral at BofA/Merrill
05/22/19 Loop Capital
Livent has 'greater value' despite adverse 2019 dynamics, says Loop Capital
05/16/19 Argus
Livent downgraded to Hold from Buy at Argus
RADA RADA Electronic
$6.30 /

-0.17 (-2.63%)

09/19/19 Alliance Global Partners
RADA price target raised to $7.50 from $6.50 at Alliance Global Partners
SPNE SeaSpine
$13.04 /

+0.49 (+3.90%)

12/12/19 Wells Fargo
SeaSpine, Glaukos double-downgraded to Underweight at Wells Fargo
12/12/19 Wells Fargo
SeaSpine downgraded to Underweight from Overweight at Wells Fargo
10/30/19 Piper Sandler
Piper Jaffray sees more upside surprises for SeaSpine
07/12/19 Piper Sandler
Piper 'strongly' encourages purchase of SeaSpine shares
PNM PNM Resources
$49.15 /

-0.64 (-1.29%)

11/21/19 Barclays
Barclays makes seven rating changes in North America Power & Utilities
11/21/19 Barclays
PNM Resources upgraded to Equal Weight from Underweight at Barclays
10/07/19 Evercore ISI
New Mexico Supreme Court decision a setback for PNM Resources, says Evercore ISI
09/30/19 BofA
PNM Resources upgraded to Buy on likelihood of NM plan success at BofA/Merrill
  • 08
    Jan
  • 08
    Jan
  • 08
    Jan
Hot Stocks
Greenlane, AVD announce distribution agreement » 17:01
01/07/20
01/07
17:01
01/07/20
17:01
GNLN

Greenlane

$3.03 /

-0.06 (-1.94%)

Advanced Vapor Devices,…

Advanced Vapor Devices, or AVD, and Greenlane Holdings (GNLN) announced a comprehensive distribution agreement for AVD products, including its entire suite of glass and resin cartridges, glass disposable cartridges, and rechargeable and disposable batteries. Under the terms of the agreement, Greenlane will distribute AVD's Easy-Press Glass Cartridge, the industry's first glass cartridge with a thumb snap-on, tamper-proof locking system, which is designed to reduce bottlenecks in rapid high-end, high-production filling and capping environments.

ShowHide Related Items >><<
GNLN Greenlane
$3.03 /

-0.06 (-1.94%)

10/07/19 Roth Capital
Greenlane price target lowered to $10 from $18.50 at Roth Capital
06/21/19
Former FDA head sees difficulty in JUUL getting PMTA approval, says Cowen
06/20/19 Cowen
Greenlane fundamentals remain intact, selloff 'overdone,' says Cowen
05/14/19 Roth Capital
Greenlane initiated with a Buy at Roth Capital
Hot Stocks
Greenlane CEO buys 56.4K shares of common stock » 16:23
11/15/19
11/15
16:23
11/15/19
16:23
GNLN

Greenlane

$3.36 /

-0.05 (-1.47%)

In a regulatory filing,…

In a regulatory filing, Greenlane disclosed that its CEO Aaron LoCascio bought 56.4K shares of common stock on November 13th-14th. The total transaction size was $185K.

ShowHide Related Items >><<
GNLN Greenlane
$3.36 /

-0.05 (-1.47%)

10/07/19 Roth Capital
Greenlane price target lowered to $10 from $18.50 at Roth Capital
06/21/19
Former FDA head sees difficulty in JUUL getting PMTA approval, says Cowen
06/20/19 Cowen
Greenlane fundamentals remain intact, selloff 'overdone,' says Cowen
05/14/19 Roth Capital
Greenlane initiated with a Buy at Roth Capital
Earnings
Greenlane reports Q3 EPS (64c), consensus (3c) » 07:00
11/08/19
11/08
07:00
11/08/19
07:00
GNLN

Greenlane

$3.92 /

-0.37 (-8.62%)

Reports Q3 revenue…

Reports Q3 revenue $44.9M, consensus $50.11M.

ShowHide Related Items >><<
GNLN Greenlane
$3.92 /

-0.37 (-8.62%)

10/07/19 Roth Capital
Greenlane price target lowered to $10 from $18.50 at Roth Capital
06/21/19
Former FDA head sees difficulty in JUUL getting PMTA approval, says Cowen
06/20/19 Cowen
Greenlane fundamentals remain intact, selloff 'overdone,' says Cowen
05/14/19 Roth Capital
Greenlane initiated with a Buy at Roth Capital
Hot Stocks
Greenlane announces exclusive distribution agreement with Santa Cruz Shredder » 16:19
11/04/19
11/04
16:19
11/04/19
16:19
GNLN

Greenlane

$3.95 /

+0.05 (+1.28%)

Greenlane Holdings…

Greenlane Holdings announced that it has entered into an exclusive distribution agreement with Santa Cruz Shredder. The agreement became effective on October 1 and grants Greenlane exclusive distribution rights to all Santa Cruz Shredder products and tools.

ShowHide Related Items >><<
GNLN Greenlane
$3.95 /

+0.05 (+1.28%)

10/07/19 Roth Capital
Greenlane price target lowered to $10 from $18.50 at Roth Capital
06/21/19
Former FDA head sees difficulty in JUUL getting PMTA approval, says Cowen
06/20/19 Cowen
Greenlane fundamentals remain intact, selloff 'overdone,' says Cowen
05/14/19 Roth Capital
Greenlane initiated with a Buy at Roth Capital
On The Fly
Rising High: Roth sees industry potential as BofA says estimates still too high » 11:27
10/10/19
10/10
11:27
10/10/19
11:27
GNLN

Greenlane

$3.40 /

+ (+0.00%)

, CRON

Cronos Group

$8.19 /

-0.38 (-4.43%)

, ACB

Aurora Cannabis

$3.88 /

-0.23 (-5.60%)

, CGC

Canopy Growth

$20.83 /

-1.96 (-8.60%)

, HEXO

Hexo

$2.80 /

-0.88 (-23.91%)

, ALEAF

Aleafia Health

$0.00 /

+ (+0.00%)

, APHA

Aphria

$4.90 /

-0.49 (-9.09%)

, MMNFF

MedMen

$0.00 /

+ (+0.00%)

, CVSI

CV Sciences

$0.00 /

+ (+0.00%)

, CTST

CannTrust

$0.96 /

-0.0778 (-7.48%)

, CANN

General Cannabis

$0.00 /

+ (+0.00%)

, IGC

India Globalization Capital

$0.88 /

+0.009 (+1.03%)

, TLRY

Tilray

$21.87 /

-1.96 (-8.22%)

, TCNNF

Trulieve Cannabis

$0.00 /

+ (+0.00%)

, ZYNE

Zynerba

$7.60 /

+ (+0.00%)

In this week's "Rising…

Open Full Text

ShowHide Related Items >><<
GNLN Greenlane
$3.40 /

+ (+0.00%)

10/07/19 Roth Capital
Greenlane price target lowered to $10 from $18.50 at Roth Capital
06/21/19
Former FDA head sees difficulty in JUUL getting PMTA approval, says Cowen
06/20/19 Cowen
Greenlane fundamentals remain intact, selloff 'overdone,' says Cowen
05/14/19 Roth Capital
Greenlane initiated with a Buy at Roth Capital
CRON Cronos Group
$8.19 /

-0.38 (-4.43%)

10/10/19 Stifel
Hexo miss further damages cannabis industry credibility, says Stifel
10/09/19 Roth Capital
Roth says low enthusiasm for cannabis stocks doesn't reflect industry potential
10/07/19 BofA
Cannabis consensus estimates still may be 30% too high, says BofA/Merrill
09/26/19 Compass Point
Cannabis banking bill should find path to passage in Senate, says Compass Point
ACB Aurora Cannabis
$3.88 /

-0.23 (-5.60%)

CGC Canopy Growth
$20.83 /

-1.96 (-8.60%)

10/01/19 Piper Sandler
Canopy Growth price target lowered to $40 from $49 at Piper Jaffray
HEXO Hexo
$2.80 /

-0.88 (-23.91%)

10/07/19 BofA
HEXO Corp downgraded to Underperform from Buy at BofA/Merrill
09/20/19 MKM Partners
MKM Partners starts HEXO at Buy, sees best branded opportunity in cannabis
09/19/19 MKM Partners
HEXO Corp initiated with a Buy at MKM Partners
ALEAF Aleafia Health
$0.00 /

+ (+0.00%)

APHA Aphria
$4.90 /

-0.49 (-9.09%)

07/26/19 CIBC
Aphria downgraded to Underperformer from Neutral at CIBC
MMNFF MedMen
$0.00 /

+ (+0.00%)

09/13/19
Fly Intel: Top five analyst initiations
09/13/19 Cowen
MedMen initiated with an Underperform at Cowen
07/25/19 Roth Capital
MedMen initiated with a Buy at Roth Capital
02/21/19 Seaport Global
MedMen initiated with a Buy at Seaport Global
CVSI CV Sciences
$0.00 /

+ (+0.00%)

09/25/19 Piper Sandler
CV Sciences, Charlotte's Web offer most upside on CBD catalysts, says Piper
08/13/19 Piper Sandler
CV Sciences initiated with an Overweight at Piper Jaffray
CTST CannTrust
$0.96 /

-0.0778 (-7.48%)

07/12/19
CannTrust downgraded to Sell from Neutral at Eight Capital
07/09/19 Roth Capital
CannTrust downgraded to Neutral from Buy at Roth Capital
07/08/19
CannTrust downgraded to Neutral from Buy at Eight Capital
07/08/19 BofA
BofA double downgrades CannTrust to Underperform after Health Canada probe
CANN General Cannabis
$0.00 /

+ (+0.00%)

06/10/19 Piper Sandler
Cannabis regulation could become top 2020 election issue, says Piper Jaffray
03/14/19 Cowen
Narrow U.S. cannabis bills have better prospects than broad ones, says Cowen
IGC India Globalization Capital
$0.88 /

+0.009 (+1.03%)

TLRY Tilray
$21.87 /

-1.96 (-8.22%)

09/20/19 MKM Partners
MKM Partners starts Tilray at Neutral, says consensus too high
TCNNF Trulieve Cannabis
$0.00 /

+ (+0.00%)

09/12/19 Compass Point
Trulieve Cannabis initiated with a Neutral at Compass Point
ZYNE Zynerba
$7.60 /

+ (+0.00%)

09/19/19 H.C. Wainwright
Zynerba selloff on open-label data for Zygel 'unwarranted,' says H.C. Wainwright
09/19/19 Canaccord
Zynerba data confusion creates buying opportunity, says Canaccord
09/16/19 Jefferies
Zynerba assumed with a Hold at Jefferies
Conference/Events
Odeon Capital consumer analysts to hold an analyst/industry conference call » 10:25
10/08/19
10/08
10:25
10/08/19
10:25
TPB

Turning Point Brands

$23.90 /

-0.11 (-0.46%)

, PM

Philip Morris

$76.98 /

-0.22 (-0.28%)

, MO

Altria Group

$42.43 /

+0.38 (+0.90%)

, MMNFF

MedMen

$0.00 /

+ (+0.00%)

, GNLN

Greenlane

$3.46 /

-0.01 (-0.29%)

, BTI

British American Tobacco

$34.47 /

-0.275 (-0.79%)

Consumer Products/Tobacco…

Consumer Products/Tobacco Analysts, along with a consultant who owns a vaping company, will discuss the current state of vaping affairs including the regulatory status and possible outcomes, state actions and possible increase in these, and why this is being seen in the U.S. and not in the EU or China on an Analyst/Industry conference call to be held on October 8 at 11 am.

ShowHide Related Items >><<
TPB Turning Point Brands
$23.90 /

-0.11 (-0.46%)

09/20/19 B. Riley FBR
Turning Point trades at 34% discount to core segments, says B. Riley FBR
03/12/19 B. Riley FBR
Turning Point Brands price target raised to $55 from $45 at B. Riley FBR
PM Philip Morris
$76.98 /

-0.22 (-0.28%)

10/01/19
Fly Intel: Top five analyst upgrades
10/01/19 BofA
Philip Morris upgraded to Buy from Neutral at BofA/Merrill
10/01/19 BofA
Philip Morris upgraded to Buy from Neutral at BofA/Merrill
09/26/19 Wells Fargo
Wells Fargo not surprised Philip Morris, Altria Group ended merger talks
MO Altria Group
$42.43 /

+0.38 (+0.90%)

10/07/19 Wells Fargo
Altria Group's competitive moat widens with iQOS, says Wells Fargo
09/24/19 Morgan Stanley
Altria could rise 20%+ if deal an acquisition, not merger, says Morgan Stanley
MMNFF MedMen
$0.00 /

+ (+0.00%)

09/13/19
Fly Intel: Top five analyst initiations
09/13/19 Cowen
MedMen initiated with an Underperform at Cowen
07/25/19 Roth Capital
MedMen initiated with a Buy at Roth Capital
02/21/19 Seaport Global
MedMen initiated with a Buy at Seaport Global
GNLN Greenlane
$3.46 /

-0.01 (-0.29%)

10/07/19 Roth Capital
Greenlane price target lowered to $10 from $18.50 at Roth Capital
06/21/19
Former FDA head sees difficulty in JUUL getting PMTA approval, says Cowen
06/20/19 Cowen
Greenlane fundamentals remain intact, selloff 'overdone,' says Cowen
05/14/19 Roth Capital
Greenlane initiated with a Buy at Roth Capital
BTI British American Tobacco
$34.47 /

-0.275 (-0.79%)

09/12/19 Citi
E-vapor regulation to hit Juul hard, 'odd time' for merger talks, says Citi
08/28/19 JPMorgan
Philip Morris selloff on Altria merger talks overdone, says JPMorgan
08/27/19 Citi
Citi sees no antitrust reason to stop Philip Morris, Altria deal
07/16/19 Wells Fargo
Wells says Nielsen restatement could be positive for Monster, tobacco stocks

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.